ENDRA Life Sciences Inc (NASDAQ: NDRA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.
ENDRA Life Sciences Inc. (NDRA)
US:NASDAQ Investor Relations:
investors.endrainc.com/prviewer/release_only/id/2807436
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
NDRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NDRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NDRA alerts
High impacting ENDRA Life Sciences Inc. news events
Weekly update
A roundup of the hottest topics
NDRA
News
- ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price RequirementBusiness Wire
- ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update [Yahoo! Finance]Yahoo! Finance
- ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business UpdateBusiness Wire
- Study Highlighting ENDRA Life Sciences’ TAEUS Technology in Patients with High BMI to be Presented at AASLD’s The Liver Meeting® 2024Business Wire
- ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European PatentBusiness Wire
NDRA
Sec Filings
- 11/21/24 - Form 10-Q/A
- 11/19/24 - Form 10-Q
- 11/15/24 - Form 8-K
- NDRA's page on the SEC website